Study to Evaluate the Effect of Secukinumab Compared to Placebo on Aortic Vascular Inflammation in Subjects With Moderate to Severe Plaque Psoriasis

NCT02690701 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

91

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Plaque Psoriasis

Interventions

DRUG: Secukinumab 300 mg
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals